Shots:

• GSK will utilize its adjuvant platform technology for developing a vaccine against the 2019-nCoV virus. The use of adjuvant technology lead to the production of more vaccine- thus increasing the availability to more people
• GSK will engage with entities funded by the CEPI with the first of these agreements have been signed with Australia’s University of Queensland- which entered in an agreement with CEPI to develop a molecular clamp vaccine platform in Jan’2019
• Both CEPI and GSK are committed to principles of equitable access and will work together to ensure that the principle governs the development- use- and access of 2019-nCoV vaccine developed via collaboration

Click here ­to­ read full press release/ article 

Ref: GSK | Image: GSK